FDA Approves Teva's New Schizophrenia Drug, Boosting Stock
Translated & summarized from Now 14 by baba
The FDA has approved Teva Pharmaceutical Industries' new schizophrenia drug, Weltruza, a monthly injection that does not require post-administration medical supervision. The approval led to a roughly 4% rise in Teva's stock on Wall Street. Weltruza is based on olanzapine and aims to offer a more convenient treatment option for the estimated 1.5 million Americans receiving schizophrenia medication. Investors are optimistic about the drug's potential to boost Teva's branded pharmaceutical business.
The story in 5 lines · by baba
- The FDA approved Teva's new schizophrenia drug, Weltruza, a monthly subcutaneous injection.
- Weltruza does not require medical supervision after administration, unlike older olanzapine injections.
- Teva's stock rose approximately 4% on Wall Street following the FDA's dramatic approval.
- The drug targets a significant market of schizophrenia patients in the U.S., including oral olanzapine users.
- Investors hope Weltruza will contribute to Teva's growth in branded pharmaceuticals.
The U.S. Food and Drug Administration (FDA) has granted dramatic approval to Teva Pharmaceutical Industries for Weltruza, a new monthly subcutaneous injection for adults with schizophrenia. The drug, based on the established antipsychotic active ingredient olanzapine, offers a significant advantage by not requiring medical supervision after administration, unlike older olanzapine injections which necessitate a three-hour observation period due to a rare risk of rapid drug release. Teva anticipates launching Weltruza in the U.S. in the coming weeks, available in three dosages: 318, 425, and 531 mg. A marketing authorization application was submitted in Europe in May 2026 and is currently under review.
Weltruza's innovation lies in its extended-release formulation, making the treatment potentially more convenient and accessible for both patients and healthcare providers. While the active ingredient remains olanzapine, and thus its known side effects persist, the new delivery method eliminates the need for initial loading doses or supplementary oral medication. This development targets a significant market, with approximately 2.2 million people in the U.S. living with schizophrenia, and about 1.5 million receiving treatment. A substantial portion of these, around 300,000, currently take oral olanzapine, representing a key potential patient group for the new injection.
Long-acting injectable treatments currently account for about 13-14% of the U.S. schizophrenia treatment market, suggesting potential for growth. However, Weltruza's success will hinge on factors such as pricing, insurance coverage, and patient and physician preferences. Following the FDA announcement, Teva's stock saw a notable increase of approximately 4% on Wall Street. The company's stock has experienced a strong upward trend over the past year, with returns exceeding 100%. Investors are hopeful that Teva's innovative drugs, including Weltruza, will drive future growth and strengthen its branded pharmaceutical business beyond its generic drug operations, though regulatory approval is just the first step in realizing the drug's commercial potential.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Right 1Other 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
